The FDA issued a second tranche of Commissioner’s National Priority Vouchers (CNPVs), adding six more therapies to a pilot program designed to accelerate review of drugs deemed in the national interest. Winners include high‑profile obesity and metabolic candidates, aligning with the administration’s push to expand access to GLP‑1 and related agents. The CNPV list shortens potential review windows to 'within months' for recipients and signals a regulatory willingness to prioritize large public‑health or strategic value programs. Industry observers caution the program’s selective nature will intensify debates around allocation, domestic manufacturing conditions and downstream pricing concessions.